Journal of Orthopaedic Translation

Journal of Orthopaedic Translation is a bimonthly fully open access journal published by Elsevier since 2013 as the official journal of the Chinese Speaking Orthopaedic Society and the International Chinese Musculoskeletal Research Society, devoted to translational research in orthopaedics and musculoskeletal medicine, with a 2025 Journal Impact Factor of 9.8 which places it first among 147 orthopaedic titles《骨科转化医学》（Journal of Orthopaedic Translation）是爱思唯尔（Elsevier）自 2013 年起以双月刊形式出版的全开放获取期刊，为华语骨科学会（CSOS）与国际华人肌肉骨骼研究学会（ICMRS）的官方期刊，专注骨科与肌肉骨骼转化研究，2025 年影响因子为 9.8、在 147 种骨科期刊中排名第 1 位。

Scope

• The journal is centred on the rapidly growing field of orthopaedic translational research, and its stated rationale is that although several high quality orthopaedic journals exist, none were devoted solely to the translation of research into musculoskeletal care该刊定位于快速发展的骨科转化研究领域，其立刊理由是：高质量骨科期刊虽多，却无一专门致力于把研究转化为肌肉骨骼诊疗实践。
• Its main goal is to publish papers that identify and fill scientific knowledge gaps at the junction between basic research and clinical application, that is from bench to bedside, or community application, that is from bench to community其主要目标是发表能够发现并填补基础研究与临床应用之间——即从实验台到病床——或与社区应用之间——即从实验台到社区——知识缺口的论文。
• Original research is expected to report significant progress toward the prevention, diagnosis and treatment of musculoskeletal disorders and to serve as a template for further exploration and investment in translational orthopaedics, with multidisciplinary approaches particularly encouraged原创研究须报道肌骨骼疾病预防、诊断与治疗方面的重要进展，并为转化骨科的后续探索与投入提供范式，刊物尤其鼓励多学科交叉方法。
• Original papers are sorted into the topics of animal models, biomaterials, biophysical stimulation, clinical trials, diagnostics, health promotion, industries and markets, medical devices and implants, nutrition and drugs, regenerative medicine, regulations and policies and rehabilitation原创论文按主题归类，包括动物模型、生物材料、生物物理刺激、临床试验、诊断、健康促进、产业与市场、医疗器械与植入物、营养与药物、再生医学、法规与政策以及康复。
• The article types accepted are original research papers, review articles, editorials, perspectives, case reports and letters to the editor该刊接受的文章类型为原创研究论文、综述、社论、观点文章、病例报告与读者来信。
• As a fully open access title it charges an article publishing charge of USD 2500 for papers submitted after 1 October 2024, and it is listed as indexed in DOAJ, Embase, ScienceDirect, Scopus, the Emerging Sources Citation Index and the Science Citation Index Expanded作为完全开放获取期刊，它自 2024 年 10 月 1 日起投稿的文章收取 2500 美元的文章处理费，并自列为被（DOAJ）、（Embase）、（ScienceDirect）、（Scopus）、（ESCI）与（SCIE）收录。

History

• The first volume appeared in 2013 with an opening October issue whose lead editorial on translational medicine in orthopaedics was written by Ling Qin第 1 卷于 2013 年面世，同年 10 月的首期以（Ling Qin）撰写的骨科转化医学开篇社论领衔。^[1]
• Its publishing rhythm has widened, the publisher's page describing a quarterly release in January, April, July and October in 2017 and a bimonthly release in January, March, May, July, September and November later on, while the DOI registry shows six volumes in each of 2024, 2025 and 2026, numbered 44 to 49, 50 to 55 and 56 to 61其出版节奏不断加宽：2017 年出版方页面写明 1 月、4 月、7 月、10 月的季刊节奏，其后改为 1 月、3 月、5 月、7 月、9 月、11 月的双月刊，（DOI）注册机构显示 2024 至 2026 年每年出满 6 卷、卷号依次为 44 至 49、50 至 55 与 56 至 61。
• It belongs to two Chinese-language professional societies and carries two editorial offices, one at the Department of Orthopaedics and Traumatology of The Chinese University of Hong Kong at Prince of Wales Hospital in Hong Kong SAR, China and one at the Shanghai Key Laboratory of Orthopaedic Implants of Shanghai Ninth People's Hospital under Shanghai Jiao Tong University School of Medicine该刊归属两家华人骨科学会并设两处编辑部，一处在中国香港（Hong Kong SAR）威尔斯亲王医院的香港中文大学（The Chinese University of Hong Kong）骨科与创伤学系，另一处在上海交通大学医学院附属第九人民医院的上海市骨科内植物重点实验室（Shanghai Key Laboratory of Orthopaedic Implants）。
• Its registered output has grown to 1493 articles in the DOI registry, of which 173 were published in 2025 alone其在（DOI）注册机构的论文总量已增至 1493 篇，仅 2025 年一年就发表 173 篇。
• Its journal impact factor moved from 5.191 in 2021 and 4.889 in 2022 to 7.8 in 2024 and 9.8 in 2025, placing it at rank 1 of 147 in the orthopaedics category with a percentile above 99 and a CiteScore recorded as 13.5其影响因子从 2021 年的 5.191 与 2022 年的 4.889 升至 2024 年的 7.8 与 2025 年的 9.8，在骨科类 147 种刊中排名第 1、百分位超过 99，（CiteScore）记录为 13.5。

Editors

• The editors-in-chief are Regis O'Keefe of the Department of Orthopaedic Surgery at Washington University in St Louis in the United States and Ling Qin of the Department of Orthopaedics and Traumatology at The Chinese University of Hong Kong主编为美国圣路易斯华盛顿大学（Washington University in St Louis）骨科外科系的（Regis O'Keefe）与香港中文大学（The Chinese University of Hong Kong）骨科与创伤学系的（Ling Qin）。
• In the biography published by the journal, Qin is professor and director of the Musculoskeletal Research Laboratory at his department, holds a joint professorship at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences and is a past president of the International Chinese Musculoskeletal Research Society在该刊公布的官方简历中，（Ling Qin）任所在学系肌肉骨骼研究实验室教授兼主任，兼任中国科学院深圳先进技术研究院联合教授，并为国际华人肌肉骨骼研究学会（ICMRS）前主席。
• The publisher's page named Chih-Hwa Chen together with Ling Qin as editors-in-chief in 20172017 年出版方页面把（Chih-Hwa Chen）与（Ling Qin）并列为该刊主编。
• A 2025 editorial by Muhammad Umar and Di Chen set out the current agenda of harnessing multi-omics, smart biomaterials and regenerative immunomodulation for orthopaedic translation2025 年（Muhammad Umar）与（Di Chen）合撰的社论提出以多组学、智能生物材料与再生免疫调节重塑骨科转化的当前议题。^[2]
• Besides its standing board the journal runs guest-edited special issues and article collections, among them a collection on organs-on-chips and organoids as platforms to accelerate orthopaedic translation with enquiries handled by the editorial office in Hong Kong除常设编委会外，该刊还组织客座编辑的特刊与文章合集，其中之一为探讨器官芯片与类器官作为加速骨科转化平台的合集，相关咨询由设在香港的编辑部受理。